This study revealed that ODX-RS supported decision-making regarding postoperative adjuvant chemotherapy, especially when other tumour biomarkers, such as tumour size, grading, and Ki-67, indicated lower risk criteria. This evidence concerns the gene MKI67 and neoplasm.